Skip to content

Japt.gr

Hellenic Atherosclerosis Society
  • HOME
  • ABOUT
    • SCOPE
    • EDITORIAL BOARD
  • CURRENT ISSUE
  • ARCHIVES
    • VOLUME 14 (2023)
      • Volume 14 – Issue 1
    • VOLUME 13 (2022)
      • Volume 13 – Issue 3
      • Volume 13 – Issue 2
      • Volume 13 – Issue 1
      • Volume 13 – Suppl. 1
    • VOLUME 12 (2021)
      • Volume 12 – Issue 1
      • Volume 12 – Issue 2
      • Volume 12 – Issue 3
      • Volume 12 – Suppl. 1
    • VOLUME 11 (2020)
      • Volume 11 – Issue 1
      • Volume 11 – Issue 2
      • Volume 11 – Issue 3
      • Volume 11 – Suppl. 1
    • VOLUME 10 (2019)
      • Volume 10 – Issue 1
      • Volume 10 – Suppl. 1
    • VOLUME 9 (2018)
      • Volume 9 – Issue 1
      • Volume 9 – Issue 2
      • Volume 9 – Issue 3
      • Volume 9 – Issue 4
    • VOLUME 8 (2017)
      • Volume 8 – Issue 1
      • Volume 8 – Issue 2
      • Volume 8 – Issue 3
      • Volume 8 – Issue 4
    • VOLUME 7 (2016)
      • Volume 7 – Issue 1
      • Volume 7 – Issue 2
      • Volume 7 – Issue 3
      • Volume 7 – Issue 4
    • VOLUME 6 (2015)
      • Volume 6 – Issue 1
      • Volume 6 – Issue 2
      • Volume 6 – Issue 3
      • Volume 6 – Issue 4
    • VOLUME 5 (2014)
      • Volume 5 – Issue 1
      • Volume 5 – Issue 2
      • Volume 5 – Issue 3
    • VOLUME 4 (2013)
      • Volume 4 – Issue 1
      • Volume 4 – Issue 2
      • Volume 4 – Issue 3
    • VOLUME 3 (2012)
      • Volume 3 – Issue 3
  • FOR AUTHORS
  • SUBMIT MANUSCRIPT
  • CONTACT
  • Menu

Tag Archives: treatment

Nonalcoholic fatty liver disease

Evangelia S. Makri, Stergios A. Polyzos

 

Diagnosis of hypertension in children and adolescents: 2019 update

Stella Stabouli, Vasileios Kotsis

Is non-alcoholic steatohepatitis in lean people a risk factor for liver or cardiovascular disease?

Konstantinos Imprialos, Konstantinos Stavropoulos, Michael Doumas, Georgios Sfikas, Charalambos Koumaras, Niki Katsiki, Vasilios Athyros

Non-alcoholic fatty liver disease in HIV – infected patients without viral hepatitis What can we do about their cardiovascular risk

G. Sfikas, Chr. Boutari, K. Tassios, K. Kaitanidis, E. Mitsiou, V.G. Athyros

Non-alcoholic fatty liver disease in HIV-infected patients without viral hepatitis. What can we do about their cardiovascular risk?

Georgios Sfikas, Chrysoula Boutari, Konstandinos Tassios, Konstantinos Kaitanidis, Eydoxia Mitsiou, Vasilios G. Athyros

CURRENT ISSUE

Prof Moses Elisaf
The health benefits of olive oil in cardiovascular disease prevention: An update
Test-retest Repeatability; Integrated assessment of adherence to treatment questionnaire for Cardiometabolic Diseases
Erectile dysfunction and its correlation with arterial hypertension and cardiovascular diseases
Polygenic risk scores and personalized approaches to cardiometabolic disease prevention and treatment: A short review

Keywords

acute coronary syndrome (4) Arterial hypertension (4) arterial stiffness (5) Atherosclerosis (20) blood pressure (4) cardiovascular disease (25) cardiovascular diseases (6) cardiovascular events (3) Cardiovascular risk (6) childhood obesity (3) coronary artery disease (4) coronary heart disease (4) COVID-19 (4) diabetes mellitus (9) diet (5) dyslipidemia (14) empagliflozin (3) epidemiology (3) ezetimibe (4) Familial hypercholesterolemia (4) Heart failure (5) hypertension (8) inflammation (10) lipoproteins (4) Mediterranean diet (8) metabolic syndrome (7) morbidity (3) mortality (8) non-alcoholic fatty-liver disease (4) nonalcoholic fatty liver disease (3) obesity (8) outcome (3) PCSK9 inhibitors (4) physical activity (4) platelets (8) primary prevention (3) pulse wave velocity (3) rosuvastatin (3) smoking (3) statins (14) stroke (3) thrombin (3) thrombosis (4) treatment (5) type 2 diabetes mellitus (4)
Journal of Atherosclerosis Prevention and Treatment    ©2023
A SiteOrigin Theme